CONNECTION FOR USE IN RETINAL DISEASES
DE602019085487T2Active Publication Date: 2026-06-03ZHUHAI UNITED LAB
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- DE602019085487
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-12-04
- Filing Date
- 2019-12-18
- Publication Date
- 2026-06-03
- Estimated Expiration
- 2039-12-18
AI Technical Summary
Technical Problem
Xerophthalmia, characterized by decreased tear film stability due to abnormal tear quality or quantity, leads to eye discomfort and ocular surface inflammation, often triggered by aldehydes like malondialdehyde and 4-hydroxy-2-nonenal, which react with proteins and DNA, causing tissue damage.
Method used
A compound represented by formula (I) or its pharmaceutically acceptable salt, which binds to aldehydes in vivo through complexation, reducing aldehyde toxicity and inflammation.
Benefits of technology
The compound effectively reduces aldehyde-induced inflammation, thereby treating xerophthalmia by stabilizing the tear film and alleviating eye discomfort.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.